Meda in-licenses exclusive rights to Xerese™

Meda in-licenses exclusive rights to Xerese™

Meda has signed an exclusive licensing agreement for Xerese with the Swedish
development company Medivir AB. Xerese (formerly Lipsovir®, ME-609), used for
topical treatment of herpes labialis (cold sores), contains a combination of the
antiviral substance acyclovir and hydrocortisone. Meda's exclusive rights cover
the US, Canada and Mexico. 

Xerese is the first topical treatment indicated to both reduce the likelihood of
cold sores as well as shorten the healing time of existing cold sore lesions.
Xerese was approved by the FDA (the Food and Drug Administration) as a
prescription drug during 2009.
 
“Xerese is a very interesting addition to our product portfolio in the US. It's
already registered and has a unique and differentiating claim. When commercial
stock is in place we will launch the product. We look forward to the
collaboration with Medivir and that we together can develop new indications for
Xerese”, says Anders Lönner CEO at Meda.

In consideration for exclusive rights to Xerese, Meda will pay Medivir a total
of 5 MUSD in up-front and pre-launch milestones. Meda will also pay Medivir
double-digit royalties on sales.

If questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR	ph: +46 709-458 878


MEDA AB (publ) is a leading international specialty pharma company. Meda's
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under Large Cap
on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit
www.meda.se.